PD-L1 Expression
Cross-source consensus on PD-L1 Expression from 1 sources and 5 claims.
1 sources · 5 claims
Benefits
Risks & contraindications
Evidence quality
Other
Highlighted claims
- A retrospective series of 283 gastric cancer patients found PD-L1 positivity in only 15.5% of cases. — CapeOX (capecitabine and oxaliplatin) combined with sintilimab and bevacizumab biosimilar (IBI305) for first-line treatment of advanced gastric or oesophagogastric junction adenocarcinoma: study protocol for a single-arm, phase Ib/II trial
- At least 50% of gastric cancer patients are PD-L1 negative, limiting the potential benefit they derive from anti-PD-1 immunotherapy. — CapeOX (capecitabine and oxaliplatin) combined with sintilimab and bevacizumab biosimilar (IBI305) for first-line treatment of advanced gastric or oesophagogastric junction adenocarcinoma: study protocol for a single-arm, phase Ib/II trial
- The absence of PD-L1 biomarker stratification in the trial design is identified as a potential source of confounding by unmeasured variables. — CapeOX (capecitabine and oxaliplatin) combined with sintilimab and bevacizumab biosimilar (IBI305) for first-line treatment of advanced gastric or oesophagogastric junction adenocarcinoma: study protocol for a single-arm, phase Ib/II trial
- Patients with low or absent PD-L1 expression receive inconsistent survival benefit from anti-PD-1 combined with chemotherapy and constitute the majority of the gastric cancer population. — CapeOX (capecitabine and oxaliplatin) combined with sintilimab and bevacizumab biosimilar (IBI305) for first-line treatment of advanced gastric or oesophagogastric junction adenocarcinoma: study protocol for a single-arm, phase Ib/II trial
- The triple combination of anti-VEGF, anti-PD-1, and chemotherapy is hypothesised to be particularly beneficial in PD-L1-low or PD-L1-negative patients through augmentation of the tumour immune microenvironment. — CapeOX (capecitabine and oxaliplatin) combined with sintilimab and bevacizumab biosimilar (IBI305) for first-line treatment of advanced gastric or oesophagogastric junction adenocarcinoma: study protocol for a single-arm, phase Ib/II trial